News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Commentary

Article

February 5, 2024

Beyond Images: 2024 Trends Reshaping Healthcare with Radiopharmaceuticals

Author(s):

Jon Devries

By capitalizing on AI advancements, pushing the boundaries of personalized medicine with theranostics, and strengthening digital healthcare networks, radiopharmaceuticals are poised to transform healthcare from a reactive to a proactive discipline.

Image credit: Наталья Евтехова | stock.adobe.com

Image credit: Наталья Евтехова | stock.adobe.com

The healthcare sector is advancing rapidly, with radiopharmaceuticals at the forefront of cancer treatment. These radioactive compounds are extremely effective in both diagnosing and offering targeted therapy, heralding an era of personalized medicine. In this piece, we explore significant trends redefining the possibilities in this field with the potential to improve patient outcomes, streamline provider workflows, and optimize health system efficiency.

Enhancing Efficiency with AI Integration

Radiologists, grappling with increasing workloads and tight deadlines, are increasingly experiencing burnout that can impact patient care. In fact, a staggering 54% reported feeling burnout in 2022, up from 49% the previous year.

AI-driven software addresses this by processing exams, identifying key findings, and automating routine tasks. This not only boosts radiologist efficiency but also enhances patient care by enabling more accurate and faster diagnoses. The reduced time spent on administrative tasks allows radiologists more time for patient consultation, improving the overall healthcare experience.

Theranostics: Innovating Diagnosis and Treatment

Theranostics, which combines diagnostic and therapeutic capabilities, is transforming the approach to diseases such as prostate cancer. This method delivers targeted radiation therapy, minimizing harm to healthy tissues.

Its application extends beyond cancer, showing potential in addressing neurological conditions such as Alzheimer disease and various inflammatory diseases. Theranostics epitomizes the future of personalized medicine, offering treatments that are uniquely tailored to each patient’s biological and disease profile, offering the potential to significantly improve patient outcomes.

Expanding the Digital Framework in Healthcare

Although DICOM has been instrumental in standardizing medical image sharing, contemporary healthcare requires a more comprehensive digital infrastructure. Emerging platforms are integrating diverse data types, including radiopharmaceutical information, laboratory results, and clinical notes.

This amalgamation creates a detailed and holistic patient profile, assisting healthcare professionals across specialties in making well-informed decisions. For example, surgeons can leverage radiopharmaceutical data for intricate tumor resections, and oncologists can devise personalized treatment plans, thereby improving patient care and outcomes. These digital advancements facilitate global collaboration, extending state-of-the-art care to even the most remote locations.

Health Equity

The COVID-19 pandemic has underscored the importance of health equity, and radiology is no exception. A study published by Boston Medical Center showed that Black patients face delays in Alzheimer diagnoses compared to white and Hispanic patients.

Lead author Joshua Wibecan, MD, noted that, “obtaining access to neuroimaging is one possible barrier that delays diagnosis.” Black patients received imaging for cognitive impairment at an older age and were more likely to receive a CT scan, as opposed to the more detailed MRI.

The need for greater diversity and inclusion is crucial, highlighting the importance of collecting more comprehensive gender data to better support patients. Addressing these inequities by ensuring equitable access to advanced imaging technologies, such as MRI, is crucial in delivering timely and accurate diagnoses to all patient groups, improving treatment outcomes.

Looking Ahead: Radiopharmaceuticals Shaping Future Healthcare

These trends highlight the significant role radiopharmaceuticals could play in the future of healthcare. However, ensuring equitable access to these technologies and integrating AI in a manner that benefits all communities remain critical challenges.

By capitalizing on AI advancements, pushing the boundaries of personalized medicine with theranostics, and strengthening digital healthcare networks, radiopharmaceuticals are poised to transform healthcare from a reactive to a proactive discipline. This evolution promises a future in which prevention, diagnosis, and treatment are intricately tailored to each individual’s specific needs.

The result is a healthcare landscape that is not only more effective but also more humane and inclusive, ultimately leading to better patient care, an empowered healthcare workforce, and potentially lower overall healthcare costs.

About the Author

Jon DeVries is the CEO of Mirada Medical and has more than 20 years of experience spearheading the creation and release of innovative cloud-based healthcare initiatives that bring advanced services and technologies to providers and researchers, with the goal of improving patient care. Mirada’s technology plays an integral role in the medical practice, TeleDaaS, revolutionizing the radiopharmaceutical industry by providing dosimetry-as-a-service.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Ted Sweetser
Ted Sweetser
Ted Sweetser
Related Content
Advertisement
Peter Tummino
August 5th 2025

Computational Chemistry in Drug Discovery: Q&A with Dr. Peter Tummino

Mike Hollan
Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 5th 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 5th 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Cell and Gene Therapy Check-in 2024
August 5th 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges
August 5th 2025

Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges

Don Tracy, Associate Editor
A global survey of scientists and informaticians reveals growing AI investment across the biopharma value chain, but highlights gaps in data integration, standardization, and infrastructure that threaten to stall progress.
Stock.adobe.com
August 5th 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Related Content
Advertisement
Peter Tummino
August 5th 2025

Computational Chemistry in Drug Discovery: Q&A with Dr. Peter Tummino

Mike Hollan
Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 5th 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027
August 5th 2025

Merck to Cut 6,000 Jobs as It Aims for $3 Billion in Cost Savings by 2027

Don Tracy, Associate Editor
Facing patent expiration for its blockbuster Keytruda, Merck aims to streamline operations with significant job cuts and continued R&D investments.
Cell and Gene Therapy Check-in 2024
August 5th 2025

Cell and Gene Therapy Check-in 2024

Miranda Schmalfuhs
Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges
August 5th 2025

Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges

Don Tracy, Associate Editor
A global survey of scientists and informaticians reveals growing AI investment across the biopharma value chain, but highlights gaps in data integration, standardization, and infrastructure that threaten to stall progress.
Stock.adobe.com
August 5th 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.